Reference health
Current status of nanomedicine in the chemotherapy of breast cancer
100/100 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
The 100 checked references that resolve
resolves10.3322/caac.21492
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
resolves10.1016/j.biopha.2018.09.096
Ursolic acid a promising candidate in the therapeutics of breast cancer: Current status and future implications
resolves10.3322/caac.21397
Clinical practice guidelines on the evidence‐based use of integrative therapies during and after breast cancer treatment
resolves10.2174/1568009618666180628160211
Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery
resolves10.1007/s13346-018-0578-5
Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization
resolves10.1016/j.addr.2015.01.002
Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
resolves10.1016/j.jconrel.2017.10.036
Targeted cancer therapy through antibody fragments-decorated nanomedicines
resolves10.3390/pharmaceutics10040168
Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
resolves10.3390/ijms18091851
Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer
resolves10.1007/s12325-017-0519-6
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
resolves10.2147/ijn.s158696
Stimuli-responsive polymeric micelles for drug delivery and cancer therapy
resolves10.2174/1567201811666140609154949
Paclitaxel Formulations: Challenges and Novel Delivery Options
resolves10.1158/1078-0432.ccr-05-1634
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
resolves10.1080/10408347.2017.1416283
Characteristics, Properties and Analytical Methods of Paclitaxel: A Review
resolves10.1016/j.ijpharm.2018.03.030
Current development in the formulations of non-injection administration of paclitaxel
resolves10.18632/oncotarget.18900
Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials
resolves10.2174/1381612820666140619123255
SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
resolves10.1016/j.critrevonc.2013.08.001
Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors
resolves10.1007/s11095-010-0233-4
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
resolves10.4143/crt.2001.33.6.451
A Phase II Study of Genexol(R) (paclitaxel) in Metastatic Breast Cancer
resolves10.1007/s10549-007-9591-y
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
resolves10.4048/jbc.2014.17.4.344
A Phase II Trial of Neoadjuvant Chemotherapy with Genexol® (Paclitaxel) and Epirubicin for Locally Advanced Breast Cancer
resolves10.4143/crt.2016.289
An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
resolves10.1007/s12094-012-0883-2
Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, NanoxelTM
resolves10.4103/0253-7613.77341
Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study
resolves10.1093/annonc/mdt322
Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India
resolves10.1016/j.biopha.2008.10.001
A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors
resolves10.1016/j.fct.2012.11.004
Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts
resolves10.3892/mmr.2013.1264
Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation
resolves10.1371/journal.pone.0172803
Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes
resolves10.1016/j.drup.2016.10.003
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy
resolves10.1166/jnn.2010.1738
Influence of Polyethyleneglycol Modification on Phagocytic Uptake of Polymeric Nanoparticles Mediated by Immunoglobulin G and Complement Activation
resolves10.1517/17425247.2011.566552
Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased<i>in vivo</i>activity
resolves10.1097/cad.0000000000000182
Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index
resolves10.1016/j.ijpharm.2017.01.002
Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations
resolves10.2147/ott.s162003
Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study
resolves10.1016/j.jconrel.2017.08.030
Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation
resolves10.1016/j.addr.2011.06.017
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention
resolves10.1093/annonc/mdr519
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial
resolves10.1007/s00280-017-3279-8
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
resolves10.3816/CBC.2010.n.064
Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer
resolves10.1007/s10549-015-3415-2
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study
resolves10.1097/CAD.0b013e3283043585
Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer
resolves10.1016/j.breast.2011.02.014
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer
resolves10.1111/tbj.12975
Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience
resolves10.1200/jco.2001.19.5.1444
Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer
resolves10.3892/ijo.2014.2604
Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: A multicenter phase III study
resolves10.1016/j.breast.2010.01.018
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer
resolves10.1093/annonc/mdq392
Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I–II)
resolves10.1016/j.ejca.2011.05.005
A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer
resolves10.1016/j.ejca.2011.08.004
Myotax: A phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
resolves10.1016/j.clinthera.2013.10.009
Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer
resolves10.1158/1078-0432.ccr-08-1046
Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel
resolves10.1159/000151352
Nine Months to Progression Using Fourth-Line Liposomally Encapsulated Paclitaxel against Hepatocellular Carcinoma
resolves10.1002/hed.23397
Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer
resolves10.1093/annonc/mdu025
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
resolves10.1371/journal.pone.0154009
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
resolves10.1038/sj.bjc.6603855
A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
resolves10.1007/s10637-011-9709-2
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer
resolves10.1007/s10637-016-0381-4
Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors
resolves10.1038/s41416-019-0391-z
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
resolves10.2217/fon.11.73
Lyso-Thermosensitive Liposomal Doxorubicin: An Adjuvant to Increase The Cure Rate of Radiofrequency Ablation in Liver Cancer
resolves10.1200/jco.2014.32.15_suppl.e15143
Standardized radiofrequency ablation (sRFA) ≥ 45 minutes (m) plus lyso-thermosensitive liposomal doxorubicin (LTLD) for solitary hepatocellular carcinoma (HCC) lesions 3-7 cm: A retrospective analysis of phase III HEAT study.
resolves10.1016/s1470-2045(12)70476-x
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study
resolves10.1158/1078-0432.ccr-08-2619
Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models
resolves10.1158/0008-5472.can-15-3435
Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
resolves10.1007/s10637-012-9921-8
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
resolves10.3748/wjg.v21.i43.12234
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
resolves10.1007/s00280-016-2986-x
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle
resolves10.1200/jco.2005.05.0294
Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer
resolves10.1056/NEJMoa070956
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
resolves10.1007/s00280-012-2048-y
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies
resolves10.1200/jco.2018.36.15_suppl.e13077
Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study.
resolves10.1021/acs.bioconjchem.6b00591
New Advances in Nanotechnology-Based Diagnosis and Therapeutics for Breast Cancer: An Assessment of Active-Targeting Inorganic Nanoplatforms
resolves10.1016/j.ijpharm.2015.11.033
Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells
resolves10.1007/s11095-007-9425-y
Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells
resolves10.1080/08982104.2017.1370471
Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells
resolves10.1016/j.ijpharm.2017.05.034
Targeted co-delivery of polypyrrole and rapamycin by trastuzumab-conjugated liposomes for combined chemo-photothermal therapy
resolves10.1007/s12272-016-0707-y
Herceptin-conjugated temperature-sensitive immunoliposomes encapsulating gemcitabine for breast cancer
resolves10.2147/ijn.s124770
Targeted multidrug delivery system to overcome chemoresistance in breast cancer
resolves10.1016/j.ejpb.2017.02.020
Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy
resolves10.3109/1061186x.2014.994182
Anti-tumor activity of paclitaxel through dual-targeting lipoprotein-mimicking nanocarrier
resolves10.3390/pharmaceutics11020063
Transferrin-Conjugated Polymeric Nanoparticle for Receptor-Mediated Delivery of Doxorubicin in Doxorubicin-Resistant Breast Cancer Cells
resolves10.1016/j.jconrel.2018.10.035
Epirubicin-loaded polymeric micelles effectively treat axillary lymph nodes metastasis of breast cancer through selective accumulation and pH-triggered drug release
resolves10.1021/acs.biomac.8b01394
PEGylated Poly(α-lipoic acid) Loaded with Doxorubicin as a pH and Reduction Dual Responsive Nanomedicine for Breast Cancer Therapy
resolves10.1002/jps.24019
Preparation, Characterization, and Pharmacodynamics of Thermosensitive Liposomes Containing Docetaxel
resolves10.1007/s11095-014-1560-7
Thermosensitive Liposome Formulated Indocyanine Green for Near-Infrared Triggered Photodynamic Therapy: In Vivo Evaluation for Triple-Negative Breast Cancer
resolves10.1016/j.colsurfb.2016.10.044
Folic acid and trastuzumab conjugated redox responsive random multiblock copolymeric nanocarriers for breast cancer therapy: In-vitro and in-vivo studies
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1007/s00280-019-03910-6"><img src="https://citestamp.com/citestamped/10.1007/s00280-019-03910-6/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1007/s00280-019-03910-6)